Journal
SCIENCE
Volume 326, Issue 5950, Pages 285-289Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1178746
Keywords
-
Categories
Funding
- International AIDS Vaccine Initiative (IAVI)
- U. S. Agency for International Development (USAID)
- National Institute of Allergy and Infectious Diseases
- NIH [AI33292]
- MRC [MC_U950097145] Funding Source: UKRI
- Medical Research Council [MC_U950097145] Funding Source: researchfish
Ask authors/readers for more resources
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals, define critical epitopes for HIV vaccine design. Using a systematic approach, we have examined neutralization breadth in the sera of about 1800 HIV-1-infected individuals, primarily infected with non-clade B viruses, and have selected donors for monoclonal antibody (mAb) generation. We then used a high-throughput neutralization screen of antibody-containing culture supernatants from about 30,000 activated memory B cells from a clade A-infected African donor to isolate two potent mAbs that target a broadly neutralizing epitope. This epitope is preferentially expressed on trimeric Envelope protein and spans conserved regions of variable loops of the gp120 subunit. The results provide a framework for the design of new vaccine candidates for the elicitation of bNAb responses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available